It seems we can’t find what you’re looking for. Perhaps searching can help.
It seems we can’t find what you’re looking for. Perhaps searching can help.
Vice President, Cancer Biology
Holly Koblish has over 20 years of experience in oncology and immuno-oncology with an extensive background in drug discovery. As a seasoned discovery scientist, Holly has been a key contributor to advancing nearly a dozen molecules into the clinic, including two FDA-approved medicines. Previously, she served as Senior Director of Pharmacology at Incyte, where, in addition to leading a team of scientists, she managed programs, asset development through both internal and external collaborations, and regulatory activities. Holly holds a B.S. in biology from Rensselaer Polytechnic Institute and a Ph.D. in cell and molecular biology from the University of Pennsylvania. She completed her postdoctoral training in molecular biology at Princeton University.
Senior Vice President, Clinical Development Operations
Vice President, Clinical Development
Jim Nolan has over 18 years of industry experience in biopharmaceutical and pharmaceutical development, and leads the process development, manufacturing analytical sciences and quality functions for Ikena’s portfolio of biologics and small molecule programs. Jim was previously at Pfizer where he was Director, Nanomedicine Development and Manufacturing, and BIND Therapeutics where he was Director of Process and Analytical Development, where he led the technical development of clinical stage nanoparticle therapeutics. Prior to BIND, he was with EMD/Merck Serono for over ten years in various leadership positions within bioprocess development, while serving on global development teams for early phase clinical programs. Jim has led the technical development of a variety of clinical stage therapeutics modalities, including recombinant biologics, PEG conjugates and polymeric nanoparticle drug products. Jim received his B.S. in biology from Worcester Polytechnic Institute, an M.S. in Biological Sciences from University of Massachusetts-Lowell and holds an M.B.A. from Worcester Polytechnic Institute.
Chief Scientific Officer
Sergio Santillana is a medical oncologist with more than 25 years of oncology drug development and clinical practice experience. Prior to providing strategic consultancy services to a variety of life science companies, including Ikena Oncology, he was Chief Medical Officer for Merrimack Pharmaceuticals, focused on developing biologics and nanotherapeutics for solid tumors. Before joining Merrimack, he was Chief Medical Officer for ARIAD Pharmaceuticals, a commercial-stage biotechnology company that was acquired by Takeda. Under Sergio’s leadership, ARIAD obtained US regulatory approval of Brigatinib for the treatment of ALK+ NSCLC, and had continued growth of its portfolio of targeted agents in solid tumors. Preceding his executive role at ARIAD, he served in various oncology clinical development leadership roles at Takeda, GlaxoSmithKline and Eli Lilly. Before entering the biopharma industry, he was a practicing board-certified medical oncologist for 15 years, including tenure at the National Cancer Institute of Peru (INEN) where his research focus was in clinical studies of novel agents. He holds an M.D. and B.S. from the Universidad Nacional Federico Villarreal School of Medicine in Lima, Peru and a M.Sc. in Experimental Therapeutics from Kellogg College at the University of Oxford. He also holds an MBA from the MIT Sloan School of Management.
PRESIDENT AND CHEIF EXECUTIVE OFFICER
Mark Manfredi is a founding member of Ikena Oncology and has over two decades of experience in cancer drug discovery and translational research. He previously served as Chief Scientific Officer of Raze Therapeutics and as Entrepreneur-in-Residence at Atlas Venture, and prior to that served as Vice President of Oncology at Takeda Pharmaceuticals where he was a member of the senior R&D management team responsible for global oncology R&D strategy. During his time at Takeda, the Oncology organization advanced eight novel mechanisms into the clinic, including ixazomib, which was recently approved by the FDA for the treatment of multiple myeloma. Mark is currently an advisor at Atlas Venture. He earned his B.S. from the University of Rhode Island and his Ph.D. in Biology from Boston College.